HRP20100160T1 - Pripravak koji sadrži roziglitazon i metformin - Google Patents
Pripravak koji sadrži roziglitazon i metformin Download PDFInfo
- Publication number
- HRP20100160T1 HRP20100160T1 HR20100160T HRP20100160T HRP20100160T1 HR P20100160 T1 HRP20100160 T1 HR P20100160T1 HR 20100160 T HR20100160 T HR 20100160T HR P20100160 T HRP20100160 T HR P20100160T HR P20100160 T1 HRP20100160 T1 HR P20100160T1
- Authority
- HR
- Croatia
- Prior art keywords
- dosage form
- oral dosage
- form according
- core
- coating
- Prior art date
Links
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 title claims abstract 11
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract 10
- 229960003105 metformin Drugs 0.000 title claims abstract 10
- 229960004586 rosiglitazone Drugs 0.000 title 1
- 239000006186 oral dosage form Substances 0.000 claims abstract 23
- 239000011248 coating agent Substances 0.000 claims abstract 17
- 238000000576 coating method Methods 0.000 claims abstract 17
- 150000003839 salts Chemical class 0.000 claims abstract 13
- 239000012453 solvate Substances 0.000 claims abstract 12
- 239000000463 material Substances 0.000 claims 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 2
- 102220570135 Histone PARylation factor 1_L30D_mutation Human genes 0.000 claims 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000002702 enteric coating Substances 0.000 claims 2
- 238000009505 enteric coating Methods 0.000 claims 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 2
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 claims 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical class N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0318824.0A GB0318824D0 (en) | 2003-08-11 | 2003-08-11 | Novel composition |
| PCT/EP2004/008970 WO2005013956A1 (en) | 2003-08-11 | 2004-08-09 | Novel composition comprising rosiglitazone and another antidiabetic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100160T1 true HRP20100160T1 (hr) | 2010-05-31 |
Family
ID=27840010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100160T HRP20100160T1 (hr) | 2003-08-11 | 2010-03-18 | Pripravak koji sadrži roziglitazon i metformin |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US20080206336A1 (no) |
| EP (1) | EP1663191B1 (no) |
| JP (1) | JP4714147B2 (no) |
| KR (1) | KR20060071396A (no) |
| CN (2) | CN102397551A (no) |
| AP (1) | AP2006003489A0 (no) |
| AR (1) | AR045230A1 (no) |
| AT (1) | ATE455542T1 (no) |
| AU (1) | AU2004262933B2 (no) |
| BR (1) | BRPI0413419A (no) |
| CA (1) | CA2534480A1 (no) |
| CY (1) | CY1109923T1 (no) |
| DE (1) | DE602004025257D1 (no) |
| DK (1) | DK1663191T3 (no) |
| EA (2) | EA200800966A1 (no) |
| EC (1) | ECSP066338A (no) |
| ES (1) | ES2339554T3 (no) |
| GB (1) | GB0318824D0 (no) |
| HK (1) | HK1092051A1 (no) |
| HR (1) | HRP20100160T1 (no) |
| IL (1) | IL173177A0 (no) |
| IS (1) | IS2745B (no) |
| MA (1) | MA27996A1 (no) |
| MX (1) | MXPA06001629A (no) |
| MY (1) | MY151053A (no) |
| NO (1) | NO20061161L (no) |
| NZ (1) | NZ544632A (no) |
| OA (1) | OA13233A (no) |
| PE (1) | PE20050357A1 (no) |
| PL (1) | PL1663191T3 (no) |
| PT (1) | PT1663191E (no) |
| SG (1) | SG165178A1 (no) |
| SI (1) | SI1663191T1 (no) |
| TW (1) | TW200517146A (no) |
| UA (1) | UA82537C2 (no) |
| UY (1) | UY28461A1 (no) |
| WO (1) | WO2005013956A1 (no) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY125516A (en) * | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
| GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
| US8637512B2 (en) * | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
| JP2007512350A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール組成物の治療および送達方法 |
| US20100323015A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
| US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
| CA2731008A1 (en) * | 2008-07-18 | 2010-01-21 | Valeant Pharmaceuticals International | Modified release formulation and methods of use |
| WO2011161521A1 (en) * | 2010-06-21 | 2011-12-29 | Lupin Limited | Compositions comprising metformin and rosiglitazone |
| CA2804926C (en) * | 2010-07-09 | 2019-01-08 | James Trinca Green | Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin |
| CN102727459A (zh) * | 2011-04-15 | 2012-10-17 | 江苏豪森医药集团有限公司 | 一种具有第一和第二活性药物的制剂 |
| CN118001246A (zh) * | 2024-01-31 | 2024-05-10 | 四川鲁徽制药有限责任公司 | 一种达格列净、吡格列酮复方缓释片及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| GB8820353D0 (en) * | 1988-08-26 | 1988-09-28 | Staniforth J N | Controlled release tablet |
| US5952509A (en) * | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
| GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
| US20010049380A1 (en) * | 1997-06-18 | 2001-12-06 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and sulphonylurea |
| US20020004515A1 (en) * | 1997-06-18 | 2002-01-10 | Smith Stephen Alistair | Treatment of diabetes with thiazolidinedione and metformin |
| US20020006939A1 (en) * | 1997-10-13 | 2002-01-17 | Smithkline Beecham P.L.C. | Use of thiazolidinediones for the treatment of hyperglycaemia |
| DE69917618T2 (de) * | 1998-04-03 | 2005-06-23 | Egalet A/S | Zusammensetzung mit kontrollierter wirkstoff-freisetzung |
| US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
| UA67802C2 (uk) * | 1998-10-23 | 2004-07-15 | Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. | Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції |
| EP1001014B1 (en) * | 1998-11-10 | 2006-01-11 | The Procter & Gamble Company | Bleaching compositions |
| US20040102486A1 (en) * | 1998-11-12 | 2004-05-27 | Smithkline Beecham Corporation | Novel method of treatment |
| US20040081697A1 (en) * | 1998-11-12 | 2004-04-29 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| US20030153607A1 (en) * | 1998-11-12 | 2003-08-14 | Smithkline Beecham P.L.C. | Novel composition and use |
| AU768994B2 (en) * | 1998-11-12 | 2004-01-15 | Smithkline Beecham Plc | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| JP2003514011A (ja) * | 1999-11-16 | 2003-04-15 | スミスクライン ビーチャム パブリック リミテッド カンパニー | チアゾリジンジオン−塩酸メトホルミンを含む医薬組成物 |
| AU5745601A (en) * | 2000-05-01 | 2001-11-12 | Aeropharm Technology Inc | A core formulation |
| GB0027471D0 (en) * | 2000-11-08 | 2000-12-27 | Smithkline Beecham Plc | Processes |
| GB0120835D0 (en) * | 2001-08-28 | 2001-10-17 | Smithkline Beecham Plc | Process |
| GB0127805D0 (en) * | 2001-11-20 | 2002-01-09 | Smithkline Beecham Plc | Pharmaceutical composition |
| PE20030800A1 (es) * | 2002-02-12 | 2003-10-31 | Glaxo Group Ltd | Forma de dosificacion oral de liberacion controlada |
| GB0203296D0 (en) * | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
| US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
-
2003
- 2003-08-11 GB GBGB0318824.0A patent/GB0318824D0/en not_active Ceased
-
2004
- 2004-08-09 NZ NZ544632A patent/NZ544632A/en not_active IP Right Cessation
- 2004-08-09 SG SG200901679-1A patent/SG165178A1/en unknown
- 2004-08-09 AR ARP040102846A patent/AR045230A1/es not_active Application Discontinuation
- 2004-08-09 US US10/567,803 patent/US20080206336A1/en not_active Abandoned
- 2004-08-09 DE DE602004025257T patent/DE602004025257D1/de not_active Expired - Lifetime
- 2004-08-09 PT PT04741403T patent/PT1663191E/pt unknown
- 2004-08-09 EP EP04741403A patent/EP1663191B1/en not_active Expired - Lifetime
- 2004-08-09 JP JP2006522974A patent/JP4714147B2/ja not_active Expired - Fee Related
- 2004-08-09 PL PL04741403T patent/PL1663191T3/pl unknown
- 2004-08-09 DK DK04741403.2T patent/DK1663191T3/da active
- 2004-08-09 TW TW093123804A patent/TW200517146A/zh unknown
- 2004-08-09 EA EA200800966A patent/EA200800966A1/ru unknown
- 2004-08-09 AU AU2004262933A patent/AU2004262933B2/en not_active Ceased
- 2004-08-09 AT AT04741403T patent/ATE455542T1/de active
- 2004-08-09 CN CN2011103143770A patent/CN102397551A/zh active Pending
- 2004-08-09 PE PE2004000771A patent/PE20050357A1/es not_active Application Discontinuation
- 2004-08-09 EA EA200600400A patent/EA011550B1/ru not_active IP Right Cessation
- 2004-08-09 CN CN2004800232304A patent/CN1835741B/zh not_active Expired - Fee Related
- 2004-08-09 KR KR1020067002884A patent/KR20060071396A/ko not_active Application Discontinuation
- 2004-08-09 ES ES04741403T patent/ES2339554T3/es not_active Expired - Lifetime
- 2004-08-09 MY MYPI20043234 patent/MY151053A/en unknown
- 2004-08-09 OA OA1200600045A patent/OA13233A/en unknown
- 2004-08-09 CA CA002534480A patent/CA2534480A1/en not_active Abandoned
- 2004-08-09 UY UY28461A patent/UY28461A1/es not_active Application Discontinuation
- 2004-08-09 BR BRPI0413419-2A patent/BRPI0413419A/pt not_active IP Right Cessation
- 2004-08-09 MX MXPA06001629A patent/MXPA06001629A/es active IP Right Grant
- 2004-08-09 SI SI200431376T patent/SI1663191T1/sl unknown
- 2004-08-09 WO PCT/EP2004/008970 patent/WO2005013956A1/en active Application Filing
- 2004-08-09 AP AP2006003489A patent/AP2006003489A0/xx unknown
- 2004-09-08 UA UAA200601353A patent/UA82537C2/uk unknown
-
2006
- 2006-01-16 IL IL173177A patent/IL173177A0/en unknown
- 2006-01-31 EC EC2006006338A patent/ECSP066338A/es unknown
- 2006-02-17 MA MA28817A patent/MA27996A1/fr unknown
- 2006-03-02 IS IS8337A patent/IS2745B/is unknown
- 2006-03-10 NO NO20061161A patent/NO20061161L/no not_active Application Discontinuation
- 2006-11-15 HK HK06112571.6A patent/HK1092051A1/xx not_active IP Right Cessation
-
2010
- 2010-03-18 HR HR20100160T patent/HRP20100160T1/hr unknown
- 2010-03-22 CY CY20101100261T patent/CY1109923T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100160T1 (hr) | Pripravak koji sadrži roziglitazon i metformin | |
| HRP20020416B1 (en) | Novel composition and use | |
| HRP20010343B1 (en) | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent | |
| DZ3316A1 (fr) | Sels de chlorhydrate de 5- 4- 2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione | |
| MY129317A (en) | Taste masked pharmaceutical compositions | |
| DE69937650D1 (de) | Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe | |
| NO20023313D0 (no) | Nye substituerte benzimidazol doseringsformer og fremgangsmåte for anvendelse av samme | |
| DE60019116D1 (de) | Neue omeprazole und (s)-omeprazole zusammensetzung | |
| EA200701680A1 (ru) | Лекарственная форма для перорального введения, содержащая розиглитазон | |
| IL146111A0 (en) | 5-[4-[2-(n-methyl-n-(2-pyridyl) amino)ethoxy]benzyl] thiazolidine-2,4-dione, maleic acid salt | |
| NO20003069L (no) | 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin- 2,4-dion-maleinsyre-salt-hydrat som farmasøytikum | |
| HRP20010342B1 (en) | Pharmaceutical composition for modified release insulin sensitiser | |
| PE20050335A1 (es) | Forma de dosificacion oral que comprende 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona y procedimiento para la preparacion | |
| AR038417A1 (es) | Forma de dosificacion oral, procedimiento para prepararla y uso de una base debil farmaceuticamente aceptable o una sal o solvato farmaceuticamente aceptable de la misma para preparar dicha forma de dosificacion oral | |
| LU90617B1 (fr) | Nouvelle forme cristalline du chlorhydrate de 6-hydroxy-3-(4-(2-(piperidin-1-Y1)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophene | |
| IL154724A0 (en) | The hydrochloride salt of 5-[4- [2- (n-methyl-n- (2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2, 4-dione | |
| WO2004004684A8 (en) | Controlled-release pharmaceutical formulations | |
| DK1446404T3 (da) | Rosiglitazonedisylater og deres anvendelse som antidiabetika | |
| IL155051A0 (en) | Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl) amino) ethoxy] benzyl] thiazolidine-2, 4-dione | |
| WO2011093612A3 (en) | Oral complex composition comprising pseudoephedrine and levocetirizine | |
| NO20025882D0 (no) | 5-(4-(2-(N-metyl-N-(2-pyridyl)amino)etoksy)benzyl)-tiazolidin- 2,4-dion hydriodid som farmasöytisk middel | |
| AR034103A1 (es) | Composicion farmaceutica que comprende ligandos de neurofilina para el tratamiento de condiciones oculares |